lifestyle.militaryparenting.org

Author: AlzeCure Pharma

AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million

April 26, 2026
Last Patient has Completed AlzeCure’s Phase Ib Clinical Study with NeuroRestore ACD856

April 20, 2026
AlzeCure Pharma Publishes its Annual Report for 2025

April 8, 2026
AlzeCure Pharma to Present at Redeye Healthcare Day on April 14

April 7, 2026
AlzeCure Pharma to Present at Redeye Alzheimer’s Theme Event on April 9

April 1, 2026
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD

March 19, 2026